fbpx

Researchers take an early step toward developing a new class of therapeutics for patients with a deadly blood cancer

The team has discovered that for acute myeloid leukemia (AML) patients, there is a dopamine receptor pathway that becomes abnormally activated in the cancer stem cells. This inspired the clinical investigation of a dopamine receptor-inhibiting drug thioridazine as a new therapy for patients, and their focus on adult AML has revealed encouraging results.

Read more
Enable notifications of new posts    OK No thanks